FiercePharmaAsia—Samsung and Merck’s Remicade biosim, Mitsubishi’s CNS buy, Takeda-Schrödinger R&D pact
admin 28th July 2017 Uncategorised 0Samsung and partner Merck have launched their Remicade biosimilar in the U.S., Mitsubishi Tanabe is buying CNS expert NeuroDerm for $1.1 billion, Takeda and Schrödinger formed a multiprogram drug discovery pact worth up to $170 million project and more.
More: FiercePharmaAsia—Samsung and Merck’s Remicade biosim, Mitsubishi’s CNS buy, Takeda-Schrödinger R&D pact
Source: fierce